Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Amgen Shares Rebound 4.1% Amid Optimism Over Differentiated OLPASIRAN Program

Guavy AI Editorial Team
Instruments
AMGN
Share

Amgen (AMGN) shares have surged by 4.1% on September 22, 2026, after a recent selloff due to concerns about the Lp(a) drug class.

An analysis suggests that investors are now warming up to the view that Amgen's olpasiran program may still be differentiated from rival programs.

The rebound is also attributed to commercial and regulatory progress for Imdelltra, which could improve uptake of the treatment.

More on Stocks

Stocks just now

Salesforce Shares Plummet After Director Buys Up $999K Worth of Stock

Stocks just now

Telstra Boosts Customer Service with AI-Powered Salesforce Partnership

Stocks just now

Salesforce Stock Slumps Despite Beating Q2 Earnings Expectations

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy